| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -6.8 | -8.6 |
| EPS (diluted, $ a share) | $-1.29 | $-3.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NXTC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
NextCure, Inc.: key numbers
- Share price
- $6.68Close, Nov 16
- Market cap
- $30.6M
- Shares outstanding
- 4.58MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from NextCure, Inc.
All →NextCure Insider ADAR1 Capital Management LLC Buys $62.9K of Stock
ADAR1 Capital Management LLC bought 12,333 shares of NextCure, Inc. at $5.10 a share, worth $62.9K in total on Nov 11, 2026. Shares held after the trade: 750,289 (+1.7%).
- Value
- $62.9K
- Shares
- 12,333
- Price
- $5.10
- Holding change
- +1.7%
- Trade date
- Nov 11, 2026
NextCure Signs $820M M&A Deal with Avere Therapeutics, Inc.
NextCure provided a status update on its pending merger with Avere Therapeutics, noting that the SEC has declared its S-4 registration statement effective and a stockholder vote is scheduled for December 9, 2026. The transaction is supported by $820 million in committed financing from a syndicate of healthcare investors to fund the development of Avere's lead inflammatory disease program, AVR-001.
- Value
- $820M
- Counterparty
- Avere Therapeutics, Inc.
“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics. Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”
Michael Richman, President and CEO of NextCure
NextCure Insider ADAR1 Capital Management LLC Buys $18.7K of Stock
ADAR1 Capital Management LLC bought 3,662 shares of NextCure, Inc. at $5.10 a share, worth $18.7K in total on Nov 6, 2026. Shares held after the trade: 737,956 (+0.5%).
- Value
- $18.7K
- Shares
- 3,662
- Price
- $5.10
- Holding change
- +0.5%
- Trade date
- Nov 6, 2026
NextCure Leadership Change
NextCure, Inc. announced that Chief Medical Officer Dr. Udayan Guha will be terminated effective October 31, 2026. The departure is in contemplation of the company's pending merger with Avere Therapeutics, Inc. Dr. Guha will receive severance benefits consistent with a termination without cause, including enhanced benefits if the merger closes.
NextCure Insider ADAR1 Capital Management LLC Buys $45.3K of Stock
ADAR1 Capital Management LLC bought 9,179 shares of NextCure, Inc. at $4.83 to $5.10 a share (average $4.93) in 2 transactions, worth $45.3K in total between Oct 23, 2026 and Oct 27, 2026. Shares held after the trade: 733,270 (+0.5%).
- Value
- $45.3K
- Shares
- 9,179
- Average price
- $4.93
- Holding change
- +0.5%
- Trade date
- Oct 23, 2026 to Oct 27, 2026
NextCure Court & Legal Update
NextCure filed a petition under Section 205 of the Delaware General Corporation Law seeking to validate a 1-for-12 reverse stock split previously implemented in July 2025. The company is seeking court validation due to uncertainty regarding the voting standard used for the split's approval in light of recent DGCL amendments and its pending merger with Avere Therapeutics. A court hearing on the validation petition is scheduled for November 6, 2026.
- Counterparty
- Delaware Court of Chancery